Adding Spinal Fluid Chemotherapy and Maintenance Chemotherapy for Young Children With HR-EBTs
Original title: Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early first test in people, so we do not yet know how well it works.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing whether young children with a brain tumor called an HR-EBT can safely get extra chemotherapy after their high dose chemotherapy.
Who this trial is for. This trial is for children under 6 years old who were newly diagnosed with HR-EBTs and have finished high dose chemotherapy. It is testing whether adding intrathecal topotecan, which is chemotherapy put into the spinal fluid, plus maintenance chemotherapy, can be done in these children.
Where it stands. There are no results yet. This is a pilot study, so the main thing being measured is whether this added treatment is workable for these children. The trial has not reported results.
What this means, and what it doesn't
What it could mean: For families of a young child with a newly diagnosed HR-EBT, this is one study being run right now. If your child might fit, you can ask your care team about it. They can tell you if it makes sense for your child's situation.
What it doesn't mean: This does not mean the treatment works. A trial is a test, not a proven treatment. Being in a trial is not a guarantee that your child will be helped. This is not a promise of a cure. It is also not something your own doctor can simply prescribe.
Source: ClinicalTrials.gov, July 14, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.